DK3476399T3 - Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf - Google Patents
Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf Download PDFInfo
- Publication number
- DK3476399T3 DK3476399T3 DK17814733.6T DK17814733T DK3476399T3 DK 3476399 T3 DK3476399 T3 DK 3476399T3 DK 17814733 T DK17814733 T DK 17814733T DK 3476399 T3 DK3476399 T3 DK 3476399T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigin
- lag
- antibody
- binding fragment
- pharmaceutical application
- Prior art date
Links
- 102000017578 LAG3 Human genes 0.000 title 1
- 101150030213 Lag3 gene Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610465386 | 2016-06-23 | ||
| PCT/CN2017/089492 WO2017219995A1 (zh) | 2016-06-23 | 2017-06-22 | Lag-3抗体、其抗原结合片段及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3476399T3 true DK3476399T3 (da) | 2022-05-30 |
Family
ID=60783834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17814733.6T DK3476399T3 (da) | 2016-06-23 | 2017-06-22 | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11155617B2 (da) |
| EP (1) | EP3476399B1 (da) |
| JP (1) | JP6998895B2 (da) |
| KR (1) | KR102497259B1 (da) |
| CN (1) | CN108472349B (da) |
| AU (1) | AU2017282892B2 (da) |
| BR (1) | BR112018074155A2 (da) |
| CA (1) | CA3024359A1 (da) |
| DK (1) | DK3476399T3 (da) |
| ES (1) | ES2915410T3 (da) |
| HU (1) | HUE058657T2 (da) |
| MX (1) | MX2018015393A (da) |
| PL (1) | PL3476399T3 (da) |
| PT (1) | PT3476399T (da) |
| RU (1) | RU2757813C2 (da) |
| TW (1) | TWI757304B (da) |
| UA (1) | UA127048C2 (da) |
| WO (1) | WO2017219995A1 (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
| CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| EP3714901A4 (en) * | 2017-12-22 | 2022-03-02 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| US11661452B2 (en) | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
| CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
| CN110606892B (zh) * | 2018-06-14 | 2023-09-26 | 华博生物医药技术（上海）有限公司 | 一种高亲和力高生物活性的lag-3抗体及其应用 |
| CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
| CN112739371A (zh) | 2018-07-26 | 2021-04-30 | 百时美施贵宝公司 | 用于治疗癌症的lag-3组合疗法 |
| SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
| MX2021004588A (es) * | 2018-10-22 | 2022-01-18 | Shanghai Genbase Biotechnology Co Ltd | Anticuerpo anti-cldn18.2 y sus usos. |
| CN111620949A (zh) * | 2019-02-28 | 2020-09-04 | 三生国健药业（上海）股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
| US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| CN112010972B (zh) * | 2019-05-31 | 2023-01-10 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CA3153777A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| CA3160479A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| WO2021136392A1 (zh) * | 2019-12-30 | 2021-07-08 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| JP2021120355A (ja) * | 2020-01-30 | 2021-08-19 | 東亞合成株式会社 | Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用 |
| JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１０およびその使用 |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| JP2023540255A (ja) | 2020-08-28 | 2023-09-22 | ブリストル－マイヤーズ スクイブ カンパニー | 肝細胞癌のためのｌａｇ－３アンタゴニスト療法 |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CN116514972B (zh) * | 2020-12-10 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody preparations and methods of using them |
| WO2022166987A1 (zh) * | 2021-02-08 | 2022-08-11 | 迈威(上海)生物科技股份有限公司 | 结合lag-3的抗体及其用途 |
| KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
| EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
| WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| EP0519866A1 (en) * | 1991-06-18 | 1992-12-23 | Ciba-Geigy Ag | Novel anti-HIV antibodies |
| USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
| JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | Ｔ細胞調節方法 |
| WO2007103225A2 (en) | 2006-03-01 | 2007-09-13 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| KR20160092061A (ko) * | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-ｄ 인자 항체 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) * | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| FR3003261B1 (fr) | 2013-03-14 | 2015-05-01 | Agronutrition | Procede de synthese d'oligomeres de glycerol acyles |
| AU2014230741B2 (en) | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
| CA2903852A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
| RU2551235C2 (ru) | 2013-08-26 | 2015-05-20 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
-
2017
- 2017-06-22 TW TW106120891A patent/TWI757304B/zh active
- 2017-06-22 JP JP2018564887A patent/JP6998895B2/ja active Active
- 2017-06-22 EP EP17814733.6A patent/EP3476399B1/en active Active
- 2017-06-22 US US16/312,174 patent/US11155617B2/en active Active
- 2017-06-22 ES ES17814733T patent/ES2915410T3/es active Active
- 2017-06-22 AU AU2017282892A patent/AU2017282892B2/en not_active Expired - Fee Related
- 2017-06-22 RU RU2018145852A patent/RU2757813C2/ru active
- 2017-06-22 PL PL17814733T patent/PL3476399T3/pl unknown
- 2017-06-22 MX MX2018015393A patent/MX2018015393A/es unknown
- 2017-06-22 CN CN201780004996.5A patent/CN108472349B/zh active Active
- 2017-06-22 HU HUE17814733A patent/HUE058657T2/hu unknown
- 2017-06-22 KR KR1020187037172A patent/KR102497259B1/ko active IP Right Grant
- 2017-06-22 CA CA3024359A patent/CA3024359A1/en active Pending
- 2017-06-22 PT PT178147336T patent/PT3476399T/pt unknown
- 2017-06-22 UA UAA201900286A patent/UA127048C2/uk unknown
- 2017-06-22 BR BR112018074155-8A patent/BR112018074155A2/pt unknown
- 2017-06-22 DK DK17814733.6T patent/DK3476399T3/da active
- 2017-06-22 WO PCT/CN2017/089492 patent/WO2017219995A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017282892A1 (en) | 2019-01-24 |
| EP3476399A4 (en) | 2020-01-29 |
| KR20190021248A (ko) | 2019-03-05 |
| US20190233513A1 (en) | 2019-08-01 |
| JP6998895B2 (ja) | 2022-01-18 |
| RU2018145852A (ru) | 2020-07-23 |
| EP3476399A1 (en) | 2019-05-01 |
| JP2019518459A (ja) | 2019-07-04 |
| US20220002405A1 (en) | 2022-01-06 |
| ES2915410T3 (es) | 2022-06-22 |
| RU2018145852A3 (da) | 2020-10-26 |
| CA3024359A1 (en) | 2017-12-28 |
| UA127048C2 (uk) | 2023-03-29 |
| WO2017219995A1 (zh) | 2017-12-28 |
| EP3476399B1 (en) | 2022-04-20 |
| HUE058657T2 (hu) | 2022-09-28 |
| TWI757304B (zh) | 2022-03-11 |
| RU2757813C2 (ru) | 2021-10-21 |
| CN108472349B (zh) | 2022-05-24 |
| US11155617B2 (en) | 2021-10-26 |
| AU2017282892B2 (en) | 2023-10-26 |
| BR112018074155A2 (pt) | 2019-03-06 |
| KR102497259B1 (ko) | 2023-02-07 |
| CN108472349A (zh) | 2018-08-31 |
| PT3476399T (pt) | 2022-05-31 |
| TW201800419A (zh) | 2018-01-01 |
| PL3476399T3 (pl) | 2022-06-20 |
| MX2018015393A (es) | 2019-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3476399T3 (da) | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf | |
| HK1247213A1 (zh) | Pd-l1抗體、其抗原結合片段及其醫藥用途 | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3515487T3 (da) | Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater | |
| DK3347379T5 (da) | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3356413T3 (da) | Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf | |
| DK3459597T3 (da) | Enkeltdomæne-antistof mod ctla4 og deraf afledt protein | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3265575T3 (da) | Cd20-bindende molekyler og anvendelser deraf | |
| DK3370768T3 (da) | Antistoffer som specifikt binder pd-1 og anvendelser deraf | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| DK3116909T3 (da) | Antistofmolekyler til lag-3 og anvendelser deraf | |
| DK3350220T3 (da) | Anti-pro/latente-myostatin-antistoffer og anvendelser deraf | |
| DK3182999T3 (da) | Anti-lag3-antistoffer og antigenbindingsfragmenter | |
| DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
| DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
| DK3710484T3 (da) | Ctla-4-bindende antistoffer og anvendelser deraf | |
| DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
| DK3362477T3 (da) | Antigenbindingsproteiner, der aktiverer leptinreceptoren | |
| DK3334500T3 (da) | Multiligand-lægemiddelskonjugater og anvendelser deraf |